Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
Roche has opened its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. The center, representing a CHF 1.2 billion investment, is designed to accelerate scientific innovation and meet patient needs. It features cutting-edge technologies and houses around 1,000 state-of-the-art laboratory and office workplaces.
The facility consists of two high-rise laboratory buildings (114m and 72m) with advanced lab technologies and digital solutions, an office building, and a convention center. In total, it offers 33 combined laboratory and office floors with 150 labs and workplaces for around 1,800 researchers. This investment is part of Roche's larger commitment to the Basel/Kaiseraugst site, totaling CHF 5.8 billion from 2009 to 2030.
Roche ha inaugurato il suo nuovo Centro di Ricerca e Sviluppo Preclinico (pRED) presso la sua sede centrale globale a Basilea, in Svizzera. Il centro, che rappresenta un investimento di 1,2 miliardi di CHF, è progettato per accelerare l'innovazione scientifica e soddisfare le esigenze dei pazienti. È dotato di tecnologie all'avanguardia e ospita circa 1.000 posti di lavoro in laboratori e uffici all'avanguardia.
La struttura è composta da due edifici per laboratori di grande altezza (114m e 72m) con tecnologie di laboratorio avanzate e soluzioni digitali, un edificio per uffici e un centro congressi. In totale, offre 33 piani combinati di laboratori e uffici con 150 laboratori e posti di lavoro per circa 1.800 ricercatori. Questo investimento fa parte dell'impegno più ampio di Roche per il sito di Basilea/Kaiseraugst, per un totale di 5,8 miliardi di CHF dal 2009 al 2030.
Roche ha inaugurado su nuevo Centro de Investigación y Desarrollo Temprano (pRED) en su sede central global en Basilea, Suiza. El centro, que representa una inversión de 1.200 millones de CHF, está diseñado para acelerar la innovación científica y satisfacer las necesidades de los pacientes. Cuenta con tecnologías de vanguardia y alberga alrededor de 1.000 puestos de trabajo en laboratorios y oficinas de última generación.
La instalación consta de dos edificios de laboratorios de gran altura (114m y 72m) con avanzadas tecnologías de laboratorio y soluciones digitales, un edificio de oficinas y un centro de convenciones. En total, ofrece 33 pisos combinados de laboratorios y oficinas con 150 laboratorios y lugares de trabajo para alrededor de 1.800 investigadores. Esta inversión forma parte del mayor compromiso de Roche con el sitio de Basilea/Kaiseraugst, totalizando 5.800 millones de CHF entre 2009 y 2030.
로슈가 스위스 바젤에 있는 글로벌 본사에 새로운 제약 연구 및 초기 개발(pRED) 센터를 개소했습니다. 이 센터는 12억 스위스 프랑의 투자를 의미하며, 과학 혁신을 가속화하고 환자의 필요를 충족하기 위해 설계되었습니다. 최첨단 기술을 갖추고 있으며, 1,000개의 최첨단 실험실과 사무실 작업 공간을 보유하고 있습니다.
이 시설은 첨단 실험실 기술과 디지털 솔루션을 갖춘 두 개의 고층 실험실 건물(114m 및 72m), 사무실 건물, 그리고 컨벤션 센터로 구성되어 있습니다. 총 33층의 종합 실험실 및 사무실 공간을 제공하며, 150개의 실험실과 약 1,800명의 연구자를 위한 작업 공간이 있습니다. 이 투자는 로슈의 바젤/카이저아우스트 부지에 대한 더 큰 헌신의 일환으로, 2009년부터 2030년까지 총 58억 스위스 프랑에 달합니다.
Roche a ouvert son nouveau Centre de recherche et de développement précoce (pRED) au sein de son siège mondial à Bâle, en Suisse. Le centre, représentant un investissement de 1,2 milliard CHF, est conçu pour accélérer l'innovation scientifique et répondre aux besoins des patients. Il dispose de technologies de pointe et abrite environ 1 000 postes de travail dans des laboratoires et bureaux à la pointe de la technologie.
Les installations comprennent deux bâtiments de laboratoire en hauteur (114 m et 72 m) avec des technologies de laboratoire avancées et des solutions numériques, un bâtiment de bureaux, et un centre de congrès. Au total, il offre 33 niveaux combinés de laboratoires et de bureaux, avec 150 laboratoires et des postes pour environ 1 800 chercheurs. Cet investissement s'inscrit dans l'engagement plus large de Roche envers le site de Bâle/Kaiseraugst, totalisant 5,8 milliards CHF de 2009 à 2030.
Roche hat sein neues Forschungs- und Entwicklungszentrum (pRED) in der globalen Zentrale in Basel, Schweiz, eröffnet. Das Zentrum, das ein Investition von 1,2 Milliarden CHF darstellt, wurde entwickelt, um wissenschaftliche Innovationen zu beschleunigen und die Bedürfnisse der Patienten zu erfüllen. Es bietet hochmoderne Technologien und beherbergt etwa 1.000 hochmoderne Labor- und Büroarbeitsplätze.
Die Einrichtung besteht aus zwei Hochhauslaboratorien (114 m und 72 m) mit fortschrittlichen Labortechnologien und digitalen Lösungen, einem Bürogebäude und einem Kongresszentrum. Insgesamt bietet es 33 kombinierte Labor- und Büroebenen mit 150 Laboren und Arbeitsplätzen für rund 1.800 Forscher. Diese Investition ist Teil von Roches größtem Engagement für den Standort Basel/Kaiseraugst, das insgesamt 5,8 Milliarden CHF von 2009 bis 2030 beträgt.
- Investment of CHF 1.2 billion in new pRED Center, demonstrating commitment to innovation
- State-of-the-art facilities with 1,000 laboratory and office workplaces
- Designed to foster collaboration and accelerate scientific discoveries
- Part of a larger CHF 5.8 billion investment in Basel/Kaiseraugst site from 2009 to 2030
- None.
- Switzerland’s most innovative research and development center underscores Roche’s long-term investment in scientific advancement to meet patient needs
- The new center will simplify and increase collaboration thereby accelerating scientific innovation
- Guy Parmelin, Federal Counsel and Head of the Federal Department of Economic Affairs, Education and Research (EAER) will attend the center’s inauguration
Basel, 10 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the opening of its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000 state-of-the-art laboratory and office workplaces, the new center brings together teams of scientists and researchers to accelerate scientific discoveries for patients.
Severin Schwan, Chairman of the Roche Group: “Roche has invested CHF 1.2 billion into the new pRED Center, underscoring our ongoing commitment to supporting Switzerland in remaining a leading innovative life sciences hub, the country where Roche was founded over 125 years ago.”
Thomas Schinecker, CEO of the Roche Group: “The new pRED Center will play an integral role in collaborating with our research centers across the globe, aiming to boost the effectiveness and efficiency of our R&D, and to deliver the greatest impact for patients.”
Hans Clevers, Head of Pharma Research and Early Development (pRED): “By investing in the new center we are continuing to push scientific frontiers to translate innovation into medicines, to better meet the needs of our patients. The new center will enable greater interaction and knowledge sharing across disciplines, for example, chemists, biologists and data scientists.”
The new pRED Center consists of two high-rise laboratory buildings (114m, 72m), with cutting-edge lab technologies and digital solutions, alongside an office building and a convention center (26m, 18m). In total, there are 33 combined laboratories and office floors with 150 labs and workplaces for around 1,800 researchers. The state-of-the-art buildings have been deliberately designed to foster collaboration and an end-to-end mindset, aiming to deliver the most transformative medicines to patients faster.
Since 2009, Roche invested 4.6 billion CHF into the Basel/Kaiseraugst site upgrade of which the inauguration of the pRED Center marks the biggest single investment. In addition, we are currently investing a further 1.2 billion CHF across the Basel site. This totals an investment of 5.8 billion CHF into the development of the Basel/Kaiseraugst site from 2009 to 2030.
For additional information and visual assets please visit www.roche.ch.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +34 620 29 25 51 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Nina Mählitz Phone: +41 79 327 54 74 | Kirti Pandey Phone: +49 172 6367262 |
| Yvette Petillon Phone: +41 79 961 92 50 | Dr. Rebekka Schnell Phone: +41 79 205 27 03 |
Attachment
FAQ
What is the total investment Roche is making in its Basel/Kaiseraugst site from 2009 to 2030?
How many researchers can the new Roche pRED Center in Basel accommodate?
What is the purpose of Roche's new pRED Center in Basel?
When did Roche (RHHBY) open its new Pharma Research and Development Center in Basel?
